David R. Brenneman

David has also represented prominent companies with respect to non-merger FTC and DOJ investigations, including, on behalf of several leading global asset managers, investigations into possible Clayton Act Section 8 violations.

David regularly counsels clients with respect to agency strategy and procedure; premerger conduct counseling; contract negotiations; merger control analysis, filings, and approvals; and substantive advocacy before various competition law authorities in the United States and abroad. David also regularly provides antitrust counseling to trade associations, standard setting organizations, and other consortiums of industry participants.

David is a member of the Morgan Lewis Committee on Foreign Investment in the United States (CFIUS) Working Group.

• Energy Harbor Corp. in connection with its $6.3 billion sale to Vistra Corp. (DOJ)
• Intercontinental Exchange, Inc. in its $16 billion proposed acquisition of Black Knight, Inc. (FTC)
• Perrigo Co. plc in its $2.1 billion acquisition of Hera SAS (HRA Pharma) (FTC)
• Leading asset manager in connection with several multibillion-dollar transactions in the publishing, healthcare, and technology industries, among others (investigations by FTC and DOJ)
• Leading asset manager in connection with several multibillion-dollar acquisitions in the telecommunications industry (investigations by DOJ)
• Leading asset manager in connection with several multi-hundred million-dollar acquisitions in the professional services industry (investigations by DOJ)
• Leading publishing company in connection with multiple transactions in the publishing industry (investigations by DOJ)
• Leading healthcare company in connection with several multibillion- and multimillion-dollar acquisitions and dispositions (investigations by FTC)
• Leading technology company in connection with a global joint venture (investigation by European Commission)
• Several leading asset managers in connection with separate DOJ investigations with respect to Section 8 of the Clayton Act (investigation by DOJ)
• Leading life sciences company in connection with FTC investigation with respect to Section 5 of the FTC Act (investigation by FTC).
• Aurobindo in connection with its proposed acquisition of Sandoz’s generic product portfolio (FTC)
• Securus Technologies (Platinum Equity) in connection with its proposed acquisition of Inmate Calling Solutions (DOJ)
• Intercontinental Exchange in connection with its acquisition of Standard & Poor’s Securities and Evaluations business from McGraw Hill Financial (investigation by DOJ)
• Pfizer Inc. in connection with its proposed $160 billion acquisition of Allergan plc (investigation by FTC)
• Perrigo Company plc in connection with Mylan N.V.’s unsolicited offer to acquire Perrigo Company plc (investigation by FTC)
• Pfizer Inc. in connection with its $68 billion acquisition of Wyeth (investigation by FTC)